Home > Insider Trading > Filing (0001181431-11-057256)

Filing Details

Accession Number:: 0001181431-11-057256
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-11-22 13:18:35
Reporting Period:: 2011-11-21

Filing Date:: 2011-11-22
Accepted Time:: 2011-11-22 13:18:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	Pharmaceutical Preparations (2834)	900475355

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1452907	New Enterprise Associates 13 Lp	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1460751	Nea 13 Gp, Ltd	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1460752	Nea Partners 13, Limited Partnership	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-11-21	1,726,248	$0.00	1,726,248	No	4	C	Direct
Common Stock	Acquisiton	2011-11-21	377,124	$0.00	2,103,372	No	4	C	Direct
Common Stock	Acquisiton	2011-11-21	1,316,299	$13.00	3,419,671	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2011-11-21	1,186,897	$0.00	409,274	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2011-11-21	1,206,897	$0.00	416,171	$0.00
Common Stock	Series B Preferred Stock	Disposition	2011-11-21	2,612,330	$0.00	900,803	$0.00
Common Stock	5% Convertible Notes due 2012	Disposition	2011-11-21	377,124	$0.00	377,124	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock, on a 2.9 for 1 basis (inadvertently reported as a 1 for 1 basis on Form 3, filed November 15, 2011), immediately prior to the closing of the Issuer's initial public offering on November 21, 2011 and had no expiration date.
The shares are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and each of the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Ryan D. Drant, Patrick J. Kerins, Krishna "Kittu" Kolluri, C. Richard Kramlich, David M. Mott, Scott D. Sandell, Ravi Viswanathan and Harry R. Weller. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Indirect Reporting Persons have no pecuniary interest.
The outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering at the Issuer's initial public offering price per share.